1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Second $20m loan for StemCells Inc alongside Capricor's first under California stem cell programme

 
• By Mandy Jackson

The California Institute of Regenerative Medicine (CIRM) has approved its second round of "disease team" awards, which included two separate $20 million loans to cardiac stem cell specialist Capricor and StemCells Inc, which won a second loan to develop its purified human neural stem cells (HuCNS-SC).

The California Institute of Regenerative Medicine (CIRM) has approved its second round of "disease team" awards, which included two separate $20 million loans to cardiac stem cell specialist Capricor and StemCells Inc, which won a second loan to develop its purified human neural stem cells (HuCNS-SC).

The three loans to two commercial enterprises from CIRM's disease team programme represent a small step toward the agency's goal of funding more therapeutic development by companies in addition to basic research at universities and other institutions (scripintelligence.com, 18 April and 8 June 2012)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapeutic Category

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.